Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Novel capsid assembly modulator shows promise in HBV

Key clinical point: A novel viral capsid assembly modulator showed promise and was usually well tolerated for treating chronic hepatitis B virus infection.

Major finding: Higher-dose cohorts showed “substantial and correlated reductions in serum HBV DNA and HBV RNA level,” especially when patients also received pegylated interferon.

Study details: Phase 1 study of 73 adults with chronic hepatitis B virus infection.

Disclosures: Novira Therapeutics developed NVR 3-778 and is a Janssen Pharmaceutical Company. Janssen provided funding for editorial support. Dr. Yuen disclosed relationships with AbbVie, Biocartis, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Ionis, Roche, Vir Biotechnology, and several other pharmaceutical companies. Other coinvestigators disclosed ties to pharmaceutical companies; eight reported employment by Novira or a Janssen company.

Citation:

Yuen MF et al. Gastroenterology. 2019 Jan 5. doi: 10.1053/j.gastro.2018.12.023.